TNGX · Tango Therapeutics, Inc.
$26.63
-0.26% last session
End-of-day data · updated 2026-07-28
Market cap
$4B
Enterprise value
$4B
Trailing P/E
—
Forward P/E
-17.6
Dividend yield
—
Beta
1.13
Avg volume
4M
Employees
0K
2D change
—
5D change
-2.66%
10D change
-6.44%
30D change
-15.09%
60D change
21.57%
MTD change
-7.00%
YTD change
201.58%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TNGX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-17
Latest call per bank · past 12 months
JP Morgan
Overweight$46.00
+72.7% vs priceJefferies
Buy$60.00
+125.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-17 | Mizuho | Maintains | Outperform | $36.00 → $40.00 |
| 2026-07-15 | JP Morgan | Initiates | Overweight | $0.00 → $46.00 |
| 2026-06-29 | Canaccord Genuity | Maintains | Buy | $42.00 → $46.00 |
| 2026-06-26 | Jefferies | Upgrade | Hold → Buy | $27.00 → $60.00 |
| 2026-06-11 | Canaccord Genuity | Maintains | Buy | $42.00 |
| 2026-06-09 | HC Wainwright & Co. | Maintains | Buy | $27.00 → $66.00 |
| 2026-06-09 | Canaccord Genuity | Maintains | Buy | $30.00 → $42.00 |
| 2026-06-08 | Leerink Partners | Maintains | Outperform | $55.00 → $69.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 44 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.2% below the 50-day MA ($26.97).
- Price vs 200-day MA: Trading 56.0% above the 200-day MA ($17.08).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.51) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($6.04) and high ($32.90).
TNGX Price Chart
Loading chart for TNGX…
Fundamentals
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.